Exicure (NASDAQ:XCUR – Get Free Report) released its quarterly earnings data on Friday. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($18.60) by $18.70, FiscalAI reports.
Exicure Price Performance
XCUR stock opened at $0.90 on Friday. Exicure has a fifty-two week low of $0.78 and a fifty-two week high of $9.48. The stock has a market capitalization of $5.89 million, a price-to-earnings ratio of -1.08 and a beta of 3.83. The business’s fifty day moving average price is $1.10 and its two-hundred day moving average price is $2.42.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Exicure in a research report on Tuesday, September 8th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.
Get Our Latest Analysis on Exicure
Exicure Company Profile
Exicure, Inc. is a biotechnology company historically focused on developing nucleic acid-based therapeutics. Its research has centered on spherical nucleic acid (SNA) technology, a platform designed to deliver genetic material into cells and influence disease-related gene activity. The company has pursued potential treatments for conditions including rare genetic disorders and cancer. Its work has included research into therapies intended to address diseases with limited treatment options. Exicure was based in Chicago, Illinois.
Read More
- Five stocks we like better than Exicure
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
